Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PROBE Patient Relevant Osteoarthritis endpoints using Big data Evaluation

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 December 2025 to 30 November 2030
Status
Running
EU funding
€14.0m
Total cost
€26.4m
Partners
46 organisations in 16 countries
Type
Research and Innovation Action
Grant agreement
101219324

What the project is doing

In the project's own words, from its summary on CORDIS.

Osteoarthritis (OA) causes pain, disability, and economic burden for 500+ million people. Developing disease modifying osteoarthritis drugs is crucial, but challenging due to disease heterogeneity, slow progression, and regulatory issues. The PROBE consortium addresses these challenges by integrating diverse and disparate datasets, combined with all necessary expertise, creating a federated database network. PROBE will unite critical mass in OA data and multidisciplinary disease specific expertise, federated infrastructure experts, AI and ML expertise, data privacy and ethics experts, health economics and outcome researchers, and indispensable patient, HTA, and regulatory perspectives experts, to achieve significant advancements in trial designs and tools for shared decision making.

The overarching aim of PROBE is to deliver data-driven opportunities for the treatment of OA, through enhancements in patient stratification, predicative modelling, patient/caregiver interface decision tools and clinical trial design. Outcomes include a federated and regulatory compliant database network of disparate OA data for powerful, innovative big data methodology. In close collaboration with key stakeholders, we will also provide novel multimodal and relevant endpoints to test emerging treatments, models to enable stratified medicine and support shared prognostic and treatment decision-making and Health Technology Assessment.

The impact of PROBE encompasses the foundation for advanced clinical trial design, predictive models for OA progression, novel endpoints, stratified patient subgroups and the ability to target treatments to patients’ needs and preferences, and tools that enable specific functional measurements and reflect real-life treatment benefits. The PROBE consortium holds the potential to reshape the landscape of OA clinical trials/treatment and ultimately improve the lives of all people affected by OA.

Topics

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Research Institute AG & Co KgWienAustriaParticipant
Sba Research Gemeinnutzige GmbHWienAustriaParticipant
Ablynx NVZwijnaardeBelgiumAssociatedpartner
MoveupBruxellesBelgiumParticipant
Universite De LiegeLiegeBelgiumParticipant
Universiteit HasseltHasseltBelgiumParticipant
Sanofi Medley Farmacêutica LtdaSão PauloBrazilAssociatedpartner
Novartis Pharma AGBaselSwitzerlandParticipant
Apheris Ai GmbHBerlinGermanyParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyParticipant
Chondrometrics GmbH - Medical Data ProcessingFreilassingGermanyParticipant
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbHNeuherbergGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Siemens Healthineers AGForchheimGermanyParticipant
Universitatsklinikum ErlangenErlangenGermanyParticipant
University of HamburgHamburgGermanyParticipant
Nordic Bioscience A/sHerlevDenmarkParticipant
Nordic Bioscience Clinical Development A/sHerlevDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Syddansk UniversitetOdense MDenmarkParticipant
Tartu UlikoolTartuEstoniaParticipant
Servizo Galego De SaudeSantiago De CompostelaSpainParticipant
Synapse Research Management Partners SLMadridSpainParticipant
Oulun YliopistoOuluFinlandParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Capgemini ConsultingIssy-Les-MoulineauxFranceParticipant
Sanofi Winthrop IndustrieGentillyFranceParticipant
Sanofi-Aventis Recherche & DeveloppementGentillyFranceAssociatedpartner
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant
Academisch Ziekenhuis LeidenLeidenNetherlandsParticipant
Sanofi B.V.AmsterdamNetherlandsAssociatedpartner
Stichting ReumaNederlandAmsterdamNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Direktoratet for Medisinske ProdukterOsloNorwayParticipant
Lunds UniversitetLundSwedenParticipant
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomParticipant
The University of NottinghamNottinghamUnited KingdomParticipant
University of LeedsLeedsUnited KingdomParticipant
University of SouthamptonSouthamptonUnited KingdomParticipant
Pacira Pharmaceuticals, Inc.WilmingtonUnited StatesParticipant
Rhino Federated Computing, Inc.BostonUnited StatesParticipant
Sanofi GenzymeCambridgeUnited StatesAssociatedpartner
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI